进展期近端胃癌不伴大弯侧侵犯的腹腔镜保脾脾门淋巴结清扫:FUGES-02随机临床试验五年结局
该研究为FUGES-02随机临床试验的事后二次分析,纳入526例不伴大弯侧侵犯的可切除进展期近端胃癌患者,比较腹腔镜全胃切除D2清扫与D2加第10组淋巴结清扫的5年生存。D2+No.10组5年无病生存率63.9% vs D2组55.1%(log-rank P=.04),5年总生存率66.2% vs 57.4%(log-rank P=.03)。
要点
- D2+No.10组5年无病生存率63.9%,D2组55.1%,log-rank P=.04。
- D2+No.10组5年总生存率66.2%,D2组57.4%,log-rank P=.03。
- D2+No.10组复发32.7%,D2组42.2%,HR 0.72(95%CI 0.54-0.95;P=.02)。
核心结论
- 该随机临床试验事后二次分析发现,腹腔镜全胃切除联合保脾脾门淋巴结清扫可改善不伴大弯侧侵犯的进展期近端胃癌的预后并减少复发。
- 原文结论指出需要未来多中心研究来验证这些发现。
研究设计与样本
- 研究为随机临床试验的事后二次分析,2015年1月5日至2018年10月10日入组536例潜在可切除的进展期近端胃癌(cT2-4a、N0或N+、M0)且不伴大弯侧侵犯的患者。
- 患者按1:1随机分配至D2+No.10组或D2组,所有患者随访至少5年,最终随访日期为2023年10月30日。
- 改良意向性治疗分析纳入526例患者(392例男性[74.5%];平均[SD]年龄60.6[9.6]岁),每组263例。
主要发现
- D2+No.10组5年无病生存率为63.9%(95%CI 58.1%-69.7%),D2组为55.1%(95%CI 49.1%-61.1%)(log-rank P=.04)。
- D2+No.10组5年总生存率为66.2%(95%CI 60.4%-71.9%),D2组为57.4%(95%CI 51.4%-63.4%)(log-rank P=.03)。
- 第10组淋巴结的治疗价值指数(TVI)为6.5,超过第8a组(TVI 3.0)、第11组(TVI 5.8)和第12a组(TVI 0.8)。
- D2+No.10组86例患者复发(累积发生率32.7%),D2组111例患者复发(累积发生率42.2%)(风险比0.72;95%CI 0.54-0.95;P=.02)。
- 多变量竞争风险回归模型显示,D2+No.10仍是术后5年累积复发率较低的独立保护因素(风险比0.75;95%CI 0.56-1.00;P=.05)。
关键数值与推荐
- D2+No.10组5年无病生存率63.9%(95%CI 58.1%-69.7%) vs D2组55.1%(95%CI 49.1%-61.1%)(log-rank P=.04)。
- D2+No.10组5年总生存率66.2%(95%CI 60.4%-71.9%) vs D2组57.4%(95%CI 51.4%-63.4%)(log-rank P=.03)。
- 复发:D2+No.10组86例(累积发生率32.7%) vs D2组111例(累积发生率42.2%)(HR 0.72;95%CI 0.54-0.95;P=.02)。
- 多变量竞争风险回归模型:D2+No.10为独立保护因素(HR 0.75;95%CI 0.56-1.00;P=.05)。
- 第10组淋巴结区域5年累积复发率:D2+No.10组0% vs D2组2.3%(n=6)(P=.01)。
临床怎么用
- 原文结论认为,腹腔镜全胃切除联合保脾脾门淋巴结清扫可改善不伴大弯侧侵犯的进展期近端胃癌的预后并减少复发。
- 原文指出需要未来多中心研究来验证这些发现。
局限性
- 原文结论指出需要未来多中心研究来验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Splenic hilar lymphadenectomy has been recommended for locally advanced proximal gastric cancer (APGC) involving the greater curvature. However, it is unclear whether laparoscopic spleen-preserving splenic hilar lymphadenectomy (LSPSHL) is associated with a long-term survival benefit for APGC without greater curvature invasion. OBJECTIVE: To present the 5-year follow-up data from a randomized clinical trial that compared laparoscopic total gastrectomy (D2 group) with D2 plus LSPSHL (D2 + No. 10 group) among patients with resectable APGC. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc secondary analysis of a randomized clinical trial that enrolled 536 patients with potentially resectable APGC (cT2-4a, N0 or N+, and M0) without greater curvature invasion from January 5, 2015, to October 10, 2018. All patients were tracked for at least 5 years. The final follow-up was on October 30, 2023. INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to the D2 + No. 10 or D2 groups. MAIN OUTCOMES AND MEASURES: The 5-year disease-free survival (DFS) and overall survival (OS) rates were measured. Recurrence patterns and causes of death were compared. RESULTS: A total of 526 patients (392 men [74.5%]; mean [SD] age, 60.6 [9.6] years) were included in the modified intent-to-treat analysis, with 263 patients in each group. The 5-year DFS rate was 63.9% (95% CI, 58.1%-69.7%) for the D2 + No. 10 group and 55.1% (95% CI, 49.1%-61.1%) for the D2 group (log-rank P = .04). A statistically significant difference was observed in the 5-year OS between the D2 + No. 10 group and the D2 group (66.2% [95% CI, 60.4%-71.9%] vs 57.4% [95% CI, 51.4%-63.4%]; log-rank P = .03). The No. 10 lymph node exhibited a therapeutic value index (TVI) of 6.5, surpassing that of Nos. 8a (TVI, 3.0), 11 (TVI, 5.8), and 12a (TVI, 0.8). A total of 86 patients in the D2 + No. 10 group (cumulative incidence, 32.7%) and 111 patients in the D2 group (cumulative incidence, 42.2%) experienced recurrence (hazard ratio, 0.72; 95% CI, 0.54-0.95; P = .02). The multivariable competing risk regression model demonstrated that D2 + No. 10 remained an independent protective factor for a lower 5-year cumulative recurrence rate after surgery (hazard ratio, 0.75; 95% CI, 0.56-1.00; P = .05). There was a significant difference in the 5-year cumulative recurrence rate at the No. 10 lymph node area between the 2 groups (D2 + No. 10 group vs D2 group: 0% vs 2.3% [n = 6]; P = .01). CONCLUSIONS: This post hoc secondary analysis of a randomized clinical trial found that laparoscopic total gastrectomy with LSPSHL can improve the prognosis and reduce recurrence for APGC without greater curvature invasion. Future multicenter studies are warranted to validate these findings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02333721.
引用
- Lin JX, Xu BB, Zheng HL, et al. Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial. JAMA Surg. 2024. PMID: 38691353. doi:10.1001/jamasurg.2024.1023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。